Notice of clarification to drug manufacturers and sponsors - Risk Management Plans - Update

This notice is being issued to clarify to drug manufacturers and sponsors that elements of Risk Management Plans (RMPs) required by Health Canada, such as controlled distribution programs, are not intended to restrict access to Canadian Reference Products (CRPs) for generic drug manufacturers for the purposes of conducting comparative testing.

Publisher
Health Canada
Resources
2
Catalogue metadata updated
2024-04-04

Data overview

Formats
HTML
File languages
English, French

Official sources and licences

Resources

Related open data